The fifth edition of the World Health Organization (WHO) histologic classification of thyroid
neoplasms released in 2022 includes newly recognized tumor types, subtypes, and a …

All endocrine glands are susceptible to neoplastic growth, yet the health consequences of
these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …

Background RET mutations occur in 70% of medullary thyroid cancers, and RET fusions
occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the …

Thyroid nodules are common, usually asymptomatic, and often pose minimal risk to the
affected patient. However, 10–15% prove malignant and serve as the rationale for …

Large panels of comprehensively characterized human cancer models, including the
Cancer Cell Line Encyclopedia (CCLE), have provided a rigorous framework with which to …

Considerable changes have occurred in the management of differentiated thyroid cancer
(DTC) during the past four decades, based on improved knowledge of the biology of DTC …

Objective: To develop evidence-based recommendations for safe, effective, and appropriate
thyroidectomy. Background: Surgical management of thyroid disease has evolved …

Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and
cell growth are common hallmarks of cancer, but the extent, mechanisms, and co …